An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors
Current anti-hepatitis B virus (HBV) regimen do not meet ideal result due to emerging resistance strains, cytotoxicity, and unfavorable adverse effects. In chronic HBV infection, high rates of sub-viral particles (SVPs) bearing HBV surface antigen (HBsAg) is a major obstacle regarding to raise effec...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-04-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fmicb.2018.00662/full |
| _version_ | 1819204513726201856 |
|---|---|
| author | Alireza Mohebbi Alireza Mohebbi Nazanin Lorestani Alireza Tahamtan Niki L. Kargar Alijan Tabarraei Alijan Tabarraei |
| author_facet | Alireza Mohebbi Alireza Mohebbi Nazanin Lorestani Alireza Tahamtan Niki L. Kargar Alijan Tabarraei Alijan Tabarraei |
| author_sort | Alireza Mohebbi |
| collection | DOAJ |
| description | Current anti-hepatitis B virus (HBV) regimen do not meet ideal result due to emerging resistance strains, cytotoxicity, and unfavorable adverse effects. In chronic HBV infection, high rates of sub-viral particles (SVPs) bearing HBV surface antigen (HBsAg) is a major obstacle regarding to raise effective immune responses and subsequently virus clearance. Development of potent HBsAg secretion inhibitors would provide a better insight into HBV immunopathogenesis and therapy. Investigating new non-toxic HBsAg secretion inhibitors targeting either viral or cellular factors could restore the immune response to remove virally infected hepatocytes after inhibiting SVPs. In this study, we overview several classes of HBV inhibitors with focus on their limitations and advantages over anti-HBsAg secretion potential. |
| first_indexed | 2024-12-23T04:37:01Z |
| format | Article |
| id | doaj.art-b22454493d33432386884c0431edf387 |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-12-23T04:37:01Z |
| publishDate | 2018-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-b22454493d33432386884c0431edf3872022-12-21T17:59:53ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2018-04-01910.3389/fmicb.2018.00662350286An Overview of Hepatitis B Virus Surface Antigen Secretion InhibitorsAlireza Mohebbi0Alireza Mohebbi1Nazanin Lorestani2Alireza Tahamtan3Niki L. Kargar4Alijan Tabarraei5Alijan Tabarraei6Student Research Committee, School of Medicine, Golestan University of Medical Sciences, Gorgan, IranDepartment of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, IranStudent Research Committee, School of Medicine, Golestan University of Medical Sciences, Gorgan, IranDepartment of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, IranStudent Research Committee, School of Medicine, Golestan University of Medical Sciences, Gorgan, IranDepartment of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, IranInfectious Disease Research Center, Golestan University of Medical Sciences, Gorgan, IranCurrent anti-hepatitis B virus (HBV) regimen do not meet ideal result due to emerging resistance strains, cytotoxicity, and unfavorable adverse effects. In chronic HBV infection, high rates of sub-viral particles (SVPs) bearing HBV surface antigen (HBsAg) is a major obstacle regarding to raise effective immune responses and subsequently virus clearance. Development of potent HBsAg secretion inhibitors would provide a better insight into HBV immunopathogenesis and therapy. Investigating new non-toxic HBsAg secretion inhibitors targeting either viral or cellular factors could restore the immune response to remove virally infected hepatocytes after inhibiting SVPs. In this study, we overview several classes of HBV inhibitors with focus on their limitations and advantages over anti-HBsAg secretion potential.http://journal.frontiersin.org/article/10.3389/fmicb.2018.00662/fullhepatitis B viruschronic hepatitis B virus infectionHBsAg inhibitorsanti-viral natural productsRNA interference |
| spellingShingle | Alireza Mohebbi Alireza Mohebbi Nazanin Lorestani Alireza Tahamtan Niki L. Kargar Alijan Tabarraei Alijan Tabarraei An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors Frontiers in Microbiology hepatitis B virus chronic hepatitis B virus infection HBsAg inhibitors anti-viral natural products RNA interference |
| title | An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors |
| title_full | An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors |
| title_fullStr | An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors |
| title_full_unstemmed | An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors |
| title_short | An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors |
| title_sort | overview of hepatitis b virus surface antigen secretion inhibitors |
| topic | hepatitis B virus chronic hepatitis B virus infection HBsAg inhibitors anti-viral natural products RNA interference |
| url | http://journal.frontiersin.org/article/10.3389/fmicb.2018.00662/full |
| work_keys_str_mv | AT alirezamohebbi anoverviewofhepatitisbvirussurfaceantigensecretioninhibitors AT alirezamohebbi anoverviewofhepatitisbvirussurfaceantigensecretioninhibitors AT nazaninlorestani anoverviewofhepatitisbvirussurfaceantigensecretioninhibitors AT alirezatahamtan anoverviewofhepatitisbvirussurfaceantigensecretioninhibitors AT nikilkargar anoverviewofhepatitisbvirussurfaceantigensecretioninhibitors AT alijantabarraei anoverviewofhepatitisbvirussurfaceantigensecretioninhibitors AT alijantabarraei anoverviewofhepatitisbvirussurfaceantigensecretioninhibitors AT alirezamohebbi overviewofhepatitisbvirussurfaceantigensecretioninhibitors AT alirezamohebbi overviewofhepatitisbvirussurfaceantigensecretioninhibitors AT nazaninlorestani overviewofhepatitisbvirussurfaceantigensecretioninhibitors AT alirezatahamtan overviewofhepatitisbvirussurfaceantigensecretioninhibitors AT nikilkargar overviewofhepatitisbvirussurfaceantigensecretioninhibitors AT alijantabarraei overviewofhepatitisbvirussurfaceantigensecretioninhibitors AT alijantabarraei overviewofhepatitisbvirussurfaceantigensecretioninhibitors |